Literature DB >> 1586658

Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes.

M C Woodle1, K K Matthay, M S Newman, J E Hidayat, L R Collins, C Redemann, F J Martin, D Papahadjopoulos.   

Abstract

Efforts to overcome rapid uptake of liposomes by cells of the mononuclear phagocytic system (MPS) have identified that lipids derivatized with the hydrophilic polymer poly(ethylene glycol) (PEG) have many advantages. The structure-function relationship of PEG-derivatized phosphatidylethanolamine (PEG-PE) has been examined by studies of blood lifetime and tissue distribution in both mice and rats. Liposomes composed of phosphatidylcholine (PC), cholesterol, and 7.5 mol% of PEG-PE show prolonged circulation and reduced MPS uptake when the PEG has a molecular weight in the range of 1000 to 5000. Up to 35% of the injected dose remains in the blood and less than 10% is taken up by the MPS (liver plus spleen) after 24 h in the best cases as compared to 1% and 40%, respectively, for liposomes without PEG-PE. Prolonged circulation with PEG-PE is independent of cholesterol, degree of saturation in either the PC or the PE lipid anchor, lipid dose, or addition of other negatively charged lipids, phosphatidylglycerol or cholesterol sulfate. This versatility in lipid composition and dose without alteration of blood lifetime or tissue distribution is essential for controlling drug dosage and release properties in a liposome-based therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586658     DOI: 10.1016/0005-2736(92)90194-q

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  31 in total

Review 1.  Drug transport to brain with targeted liposomes.

Authors:  Anita Schnyder; Jörg Huwyler
Journal:  NeuroRx       Date:  2005-01

2.  Inorganic nanovectors for nucleic acid delivery.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Anisha A D'Souza; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

Review 3.  Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.

Authors:  Sean M Geary; Aliasger K Salem
Journal:  Crit Rev Oncog       Date:  2014

4.  Effect of polyethyleneglycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes.

Authors:  K Edwards; M Johnsson; G Karlsson; M Silvander
Journal:  Biophys J       Date:  1997-07       Impact factor: 4.033

Review 5.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

6.  Diamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression.

Authors:  Laura K Moore; Edward K Chow; Eiji Osawa; J Michael Bishop; Dean Ho
Journal:  Adv Mater       Date:  2013-04-15       Impact factor: 30.849

7.  Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol).

Authors:  A K Kenworthy; S A Simon; T J McIntosh
Journal:  Biophys J       Date:  1995-05       Impact factor: 4.033

8.  Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol).

Authors:  A K Kenworthy; K Hristova; D Needham; T J McIntosh
Journal:  Biophys J       Date:  1995-05       Impact factor: 4.033

9.  Evaluation of asymmetric immunoliposomal nanoparticles for cellular uptake.

Authors:  Jeremiah Whittenton; Ramanan Pitchumani; Sundararajah Thevananther; Kishore Mohanty
Journal:  J Microencapsul       Date:  2012-06-28       Impact factor: 3.142

10.  Homoharringtonine delivered by high proportion PEG of long- circulating liposomes inhibits RPMI8226 multiple myeloma cells in vitro and in vivo.

Authors:  Miao Li; Xiong Fei; Fangfang Shi; Jun Dou; Songyan Wu; Di Wu; Yunxia Zhang; Meng Pan; Shouhua Luo; Ning Gu
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.